TORONTO, May 9, 2025 – MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical firm specializing in precision cannabinoids, is pleased to announce the release of its financial results for the first quarter, ending March 31, 2025. The release will occur before the market opens on Wednesday, May 14, 2025.
MediPharm Labs’ executive team will conduct a conference call and webcast on Wednesday, May 14, 2025, at 10:00 a.m. (Eastern time) to discuss the company’s financial performance.
Conference Call Dial-in Details:
North America Toll-Free: (888) 330-2454
International Toll: +1 (240) 789-2714
Conference ID: 4921762
Participants should dial in approximately 15 minutes before the call begins.
Webcast:
The webcast can be accessed via the following link: .
A replay of the call and webcast will be available approximately one day after the live event at: for those unable to attend live.
About MediPharm Labs
MediPharm Labs, established in 2015, focuses on developing and manufacturing purified, pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products. These processes occur within a Good Manufacturing Practices (GMP) certified facility featuring ISO standard clean rooms. MediPharm Labs has invested in a research-driven team of experts, cutting-edge technology, advanced purification methods, and specialized facilities to deliver pure, reliable, and precisely dosed cannabis products to its clientele. MediPharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to both domestic and international medical markets.
In 2021, MediPharm Labs obtained a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company to hold a commercial-scale domestic Good Manufacturing Practices License for extracting multiple natural cannabinoids. This GMP license represents the initial step in the Company’s ongoing foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., expanding MediPharm’s reach to medical patients in Canada via the Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which offers medical cannabis patients physician consultations for medical cannabis education and prescriptions.
The Company operates in accordance with all applicable laws in the countries where it conducts business.
Website:
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) as defined under applicable Canadian securities legislation. All statements, excluding historical facts, constitute forward-looking statements and are based on expectations, estimates, and projections as of the date of this release. Any statement discussing predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance, often identified by terms like “expects,” “does not expect,” “is expected,” “anticipates,” “does not anticipate,” “plans,” “budget,” “scheduled,” “forecasts,” “estimates,” “believes,” or “intends,” or variations of these terms, or indicating that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” occur or be achieved, are not historical facts and may be considered forward-looking statements. In this release, forward-looking statements pertain to the release of MediPharm’s financial results and the future of MediPharm’s foreign drug manufacturing site registration, among other things. Forward-looking statements are inherently based on numerous estimates and assumptions that, while deemed reasonable, involve known and unknown risks, uncertainties, and other factors that could cause actual results and future events to differ significantly from those expressed or implied by these statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; MediPharm’s potential inability to secure adequate financing; delays or failures in obtaining regulatory approvals; and other factors detailed in MediPharm’s filings, accessible on the SEDAR+ website at . There is no guarantee that these statements will be accurate, as actual results and future events may differ materially from those anticipated. Consequently, readers are advised not to place undue reliance on the forward-looking statements and information provided in this news release. Except as required by law, MediPharm undertakes no obligation to update any forward-looking statements, beliefs, opinions, projections, or other factors should they change.
SOURCE MediPharm Labs Corp.
“`